Analysts Offer Insights on Healthcare Companies: Aerie Pharma (NASDAQ: AERI) and Revance Therapeutics (NASDAQ: RVNC)


There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Aerie Pharma (NASDAQ: AERI) and Revance Therapeutics (NASDAQ: RVNC) with bullish sentiments.

Aerie Pharma (NASDAQ: AERI)

Canaccord Genuity analyst Dewey Steadman maintained a Buy rating on Aerie Pharma (NASDAQ: AERI) today and set a price target of $86. The company’s shares opened today at $49.95.

Steadman commented:

“We maintain our BUY rating and DCF-driven $86 PT on AERI shares.”

According to TipRanks.com, Steadman is ranked 0 out of 5 stars with an average return of -6.5% and a 34.9% success rate. Steadman covers the Healthcare sector, focusing on stocks such as ANI Pharmaceuticals Inc, Pacira Pharmaceuticals, and Cardiome Pharma Corp.

Currently, the analyst consensus on Aerie Pharma is Strong Buy and the average price target is $80.33, representing a 60.8% upside.

In a report issued on April 30, Mizuho Securities also maintained a Buy rating on the stock with a $77 price target.

Find more picks by Best Performing Analysts >>

Revance Therapeutics (NASDAQ: RVNC)

Cantor Fitzgerald analyst Louise Chen reiterated a Buy rating on Revance Therapeutics (NASDAQ: RVNC) today and set a price target of $50. The company’s shares opened today at $28.40.

Chen noted:

“Positives from the quarter that support our thesis: 1) On 01/08/18 RVNC announced interim 8-week Phase 2a results for RT002 in treating plantar fasciitis. The trial’s primary endpoint, the reduction in the patient-reported visual analog scale (VAS) for pain at Week 8, showed a robust impact on pain, with a greater than 50% reduction for patients treated with RT002.”

According to TipRanks.com, Chen is ranked 0 out of 5 stars with an average return of -11.3% and a 37.5% success rate. Chen covers the Healthcare sector, focusing on stocks such as Aclaris Therapeutics Inc, Paratek Pharmaceuticals, and Spero Therapeutics Inc.

Revance Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $49.60.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts